EP2968246A1 - Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation - Google Patents

Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Info

Publication number
EP2968246A1
EP2968246A1 EP13878433.5A EP13878433A EP2968246A1 EP 2968246 A1 EP2968246 A1 EP 2968246A1 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A1 EP2968246 A1 EP 2968246A1
Authority
EP
European Patent Office
Prior art keywords
alternatively
dpa
epa
dha
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
German (de)
English (en)
Other versions
EP2968246A4 (fr
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/fr
Publication of EP2968246A4 publication Critical patent/EP2968246A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to omega-3 fatty acid compositions, and methods of treating, preventing, reducing the occurrence of, and improving symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease or related conditions.
  • CHD coronary heart disease
  • vascular disease vascular disease
  • atherosclerotic disease or related conditions The present invention also provides methods for the treatment and/or prevention and/or reduction of cardiac events and/or cardiovascular events and/or vascular events and/or symptoms.
  • Marine oils also commonly referred to as fish oils, are a good source of the two main omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have been found to regulate lipid metabolism.
  • Omega-3 fatty acids have been found to have beneficial effects on the risk factors for cardiovascular diseases, especially mild hypertension, hypertriglyceridemia and on the coagulation factor VII phospholipid complex activity.
  • Omega-3 fatty acids lower serum triglycerides (TG), increase serum HDL-cholesterol, lower systolic and diastolic blood pressure and the pulse rate, and lower the activity of the blood coagulation factor Vll-phospholipid complex.
  • omega-3 fatty acids seem to be well tolerated, without giving rise to any severe side effects.
  • omega-3 fatty acids is a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil containing DHA ethyl esters, EPA ethyl esters as well as ethyl esters of other omega-3 fatty acids (described in USP35 for LOVAZA®) and is sold under the trademarks OMACOR® and LOVAZA®.
  • omega-3 fatty acid comprises at least 90% omega-3 fatty acids of which at least 80% EPA+DHA (in a ratio of 1.2:1 ) and is described, for example, in U.S. Pat. Nos... 5,502,077, 5,656,667 and 5,698,594.
  • LOVAZA® (omega-3-acid ethyl esters) is indicated for the treatment of patients with hypertriglyceridemia with TG levels of 500mg/dL or higher.
  • EPADEL® omega-3 fatty acid concentrate
  • This product is described as 98% EPA ethyl ester in Lancet (Vol.369; March 31 , 2007; 1090-1098) reporting on a large outcome study with EPADEL®.
  • EPADEL® is known to contain less than 1 % of any fatty acid other than EPA.
  • omega-3 fatty acid concentrate also consists almost entirely of EPA ethyl ester and is known under its developmental stage name AMR101 or its trade name VASCEPA®.
  • AMR101 is described in US patent application 2010/0278879 as comprising at least 95% EPA (typically referred to as 97% or at least 96% in company releases and references) and less than 1 % of any other fatty acid.
  • AMR101 was previously under development for the treatment of Huntingdon's Disease but failed in phase III clinical development. Subsequently, AMR101 was entered in a development program for hypertriglyceridemia and mixed dyslipidemia.
  • EPANOVATM omega-3, long chain, polyunsaturated fatty acids from fish oil containing approximately 75% DHA and EPA as free fatty acids. This product is described as comprising approximately 55% EPA and 20% DHA. EPANOVATM was previously under development for the treatment of Crohn's Disease but failed in phase III clinical development. Subsequently, EPANOVATM was entered in a development program for hypertriglyceridemia and mixed dyslipidemia.
  • omega-3 fatty acid compositions are dose dependent, i.e., the higher the dose, the greater the therapeutic affect and bioavailability.
  • the effect of each specific omega-3 fatty acid composition may be different, and therefore the level of therapeutic effect of one composition at a given dose cannot necessarily be inferred from the level of therapeutic effects of other omega-3 fatty acid compositions at the same or similar dose.
  • Omega-3 fatty acids are known to be "essential fatty acids".
  • EFAs essential fatty acids
  • the main EFAs in the diet are linoleic acid of the omega-6 series and alpha-linolenic acid of the omega-3 series. However, to fulfill most of their biological effects these "parent" EFAs must be metabolised to the other longer chain fatty acids. Each fatty acid probably has a specific role in the body.
  • n-6 series dihomo- gammalinolenic acid (DGLA, 20:3-n6) and arachidonic acid (ARA, 20:4-n6)
  • DGLA dihomo- gammalinolenic acid
  • ARA arachidonic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • U.S. Patent No. 6,479,544 describes an invention in which it is found that ARA is highly desirable rather than undesirable and it may be helpful to administer ARA in association with EPA.
  • This invention provides pharmaceutical formulations containing eicosapentaenoic acid or any appropriate derivative (hereinafter collectively referred to as EPA) and arachidonic acid (ARA), as set out in the granted claims for this patent.
  • EPA eicosapentaenoic acid or any appropriate derivative
  • ARA arachidonic acid
  • ARA may be replaced by one or more of its precursors, DGLA or GLA.
  • the ratio of EPA to ARA is preferably between 1 :1 and 20:1.
  • Patent application PCT/GB 2004/000242 describes the treatment or prevention of psoriasis with a formulation comprising more than 95% EPA and less than 2% DHA.
  • the EPA is replaced with DPA.
  • Patent application PCT/NL 2006/050291 (WO/2007/058538, GB 0301701.9) describes combinations of idigestible oligosaccharides and long chain polyunsaturated fatty acids such as ARA, EPA, DA, and combinations thereof to improve intestinal barrier integrity, improving barrier function, stimulating gut maturation and/or reducing intestinal barrier permeability.
  • Holub et al. discloses a study assessing the effect of oral supplementation with docosapentaenoic acid (DPA) on levels of serum and tissue lipid classes and their fatty acid compositions in rat liver, heart, and kidney.
  • DPA docosapentaenoic acid
  • Cardiovascular disease includes numerous problems, many of which are related to a process called atherosclerosis.
  • Atherosclerosis is a condition that develops when plaque builds up in the walls of the arteries. This buildup narrows the arteries, making it harder for blood to flow through. If a blood clot forms, it can stop the blood flow. This can cause lead to conditions or event such as myocardial infarction, stroke, heart failure, arrhythmias, valve dysfunction, and death.
  • the present invention provides omega-3 fatty acid compositions and methods of administering these compositions.
  • the present invention provides a pharmaceutical composition
  • fatty acids comprising omega-3 fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.
  • omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.
  • EPA eicosapentaenoic acid
  • DPA docos
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 70% to about 95% of the total amount of fatty acids and docosapentaenoic acid (DPA) , wherein the composition comprises no more than 5% docosahexaenoic acid (DHA) of the total amount of fatty acids, and wherein the ratio of DHA: DPA is 1 :1 or lower.
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 750 mg/g to about 950 mg/g, and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA: DPA is 1 :1 or lower.
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in a daily dosage amount of between about 1000 mg to about 5000 mg, and further comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower.
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1 :1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: docosapentaenoic acid (DPA) in an amount between about 50% to about 80% of the total amount of fatty acids, docosahexaenoic acid (DHA) in an amount between about 25% to about 40% of the total amount of fatty acids, and optionally eicosapentaenoic acid (EPA) in an amount less than about 10% of the total amount of fatty acids.
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • compositions of the present invention comprise additional fatty acids, such as heneicosapentaenoic acid (HPA), arachidonic acid (ARA), and omega-6-docosapentaenoic acid (n-6 DPA), tetracosapentaenoic acid (TPA), and/or gamma-linoleic acid (GLA).
  • HPA heneicosapentaenoic acid
  • ARA arachidonic acid
  • n-6 DPA omega-6-docosapentaenoic acid
  • TPA tetracosapentaenoic acid
  • GLA gamma-linoleic acid
  • the present invention provides methods comprising administering the compositions.
  • the present invention provides a method of treating, preventing, reducing the occurrence of, and improving symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease or related conditions, comprising administering the compositions of the present invention to a subject in need thereof.
  • the present invention also provides methods of treatment of patients by administering an effective amount of such compositions to a subject or a subject in need thereof, such as a subject prone to or afflicted with a vascular/cardiovascular disease or condition, a subject at risk of vascular/cardiovascular events, or a subject in need of treatment for a vascular/cardiovascular disease or condition.
  • the present invention provides an orally administrable composition
  • fatty acids wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1 :20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 .
  • omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the
  • the present invention provides a pharmaceutical composition
  • fatty acids comprising omega-3 fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 , and methods of using this composition.
  • the composition comprises EPA in an amount between about 70% and about 95% of the total amount of fatty acids.
  • the composition comprises less than about 5% of DHA of the total amount of fatty acids. In some embodiments, the composition comprises DPA in an amount of between about 5% and about 15% of the total amount of fatty acids. In some embodiments, the ratio of EPA to DPA (EPA:DPA) is less than about 1 :1 . In some embodiments, the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 70% to about 95% of the total amount of fatty acids and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% docosahexaenoic acid (DHA) of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
  • the composition comprises DPA in an amount of between about 5% and about 15% of the total amount of fatty acids.
  • the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
  • HPA heneicosapentaenoic acid
  • the ratio of EPA to DPA is less than about 1 :1. In some embodiments, the ratio of DHA:EPA is less than about 1 :10.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 750 mg/g to about 950 mg/g, and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
  • the composition comprises about 60 mg/g to about 120 mg/g of DPA.
  • the ratio of DHA:EPA is less than 1 :10.
  • the ratio of EPA:DPA is less than about 1 :1 .
  • the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
  • HPA heneicosapentaenoic acid
  • the present invention provides a pharmaceutical composition
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid
  • the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
  • the ratio of DHA:EPA is less than about 1 :10.
  • the ratio of EPA:DPA is less than about 1 :1.
  • the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
  • HPA heneicosapentaenoic acid
  • the present invention provides a pharmaceutical composition
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • the composition comprises docosahexaenoic acid (DHA) in an amount of less than about 30% of the total amount of fatty acids.
  • the composition comprises a daily dosage of DPA of greater than about 120 mg/day.
  • the composition comprises omega-6 fatty acids in an amount of no more than 6% of total amount of fatty acids.
  • the composition comprises DPA in an amount of at least 6% of the total amount of fatty acids.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: docosapentaenoic acid (DPA) in an amount between about 50% to about 80% of the total amount of fatty acids, docosahexaenoic acid (DHA) in an amount between about 25% to about 40% of the total amount of fatty acids, and optionally eicosapentaenoic acid (EPA) in an amount less than about 10% of the total amount of fatty acids, and methods of using the composition.
  • the composition comprises docosapentaenoic acid (DPA) in an amount between about 50% to 75%, alternatively about 50% to about 70%, alternatively about 50% to about 65%, or alternatively about 50% to about 60%, of the total amount of fatty acids.
  • the composition comprises docosahexaenoic acid (DHA) in an amount between about 25% to about 38%, alternatively about 25% to about 35%, alternatively about 30% to about 35% of the total amount of fatty acids.
  • the composition comprises eicosapentaenoic acid (EPA) in an amount less than about 9%, alternatively less than about 8%, alternatively less than about 7%, alternatively less than about 6%, alternatively less than about 5%, of the total amount of fatty acids.
  • DHA docosahexaenoic acid
  • EPA eicosapentaenoic acid
  • the compositions of the present invention comprise at least 50% omega-3 fatty acids, alternatively at least 55%, alternatively at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, alternatively at least 80%, alternatively at least 85%, alternatively at least 95%, most preferably at least 90% omega-3 fatty acids of the total amount of fatty acids.
  • the composition comprises at least about 92% to about 99%, alteratively about 93% to about 98%, alternatively about 94% to about 98%, omega- 3 fatty acids of the total amount of fatty acids.
  • EPA and DPA are jointly present in the compositions of the present invention at between about 55% and about 100% of total fatty acids, alternatively between about 60% and about 100%, alternatively between about 65% and about 100%, alternatively between about 70% and about 100%, alternatively between about 75% and about 100%, alternatively between about 80% and about 100%, alternatively between about 85% and about 95%, alternatively about 85% to about 100%, alternatively between about 85% and about 97%, alternatively between about 88% and about 95%, alternatively between about 88% and about 97%, alternatively about 88% to about 100%, alternatively between about 90% and about 95%, alternatively between about 90% and about 97%, alternatively about 90% to about 100%, alternatively about 95% to about 100%, alternatively about 97% to about 100% of the total amount of fatty acids.
  • compositions of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
  • compositions and methods of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
  • the methods and compositions of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
  • the fatty acids such as EPA and DPA
  • the fatty acids may be present in free fatty acid form, or as a salt, ester, or derivative.
  • the fatty acids are preferably composed as a triglyceride, an ester (such as an ethyl ester) or free fatty acid.
  • Other forms of the fatty acids which may be useful include salts, esters of any type, amides, mono-, di- or triglycerides, phospholipids or any other form which can lead to metabolization of the fatty acids (such as EPA and/or DPA), or the incorporation of the fatty acids (such as EPA and/or DPA) into body fluids, tissues or organs.
  • Omega-3 fatty acids may be grouped by the number of double bonds contained in the fatty acid chain.
  • HTA hexadecatrienoic acid
  • alpha- linolenic acid (ALA) and eicosatrienoic acid (ETE) are omega-3-trienoic acids
  • SDA stearidonic acid
  • ETA eicosatetraenoic acid
  • EPA heneicosapentaenoic acid
  • DPA and tetracosapentaenoic acid TPA
  • DHA and tetracosahexaenoic acid (THA) are omega-3-hexaenoic acids.
  • omega-3- pentaenoic acids will refer to a mixture of at least two omega-3 pentaenoic acids in a ratio of at least 1 :25, more preferably in a ratio of at least 1 :50, more preferably in a ratio of at least 1 :75, more preferably in a ratio of at least 1 :100, more preferably in a ratio of at least 1 :125, more preferably in a ratio of at least :150, more preferably in a ratio of at least 1 :200.
  • the ratio refers to the ratio of the least prevalent omega-3 pentaenoic acid in the mixture to the most prevalent omega- 3 pentaenoic acid in the mixture.
  • compositions of the present invention comprise EPA, HPA, DPA and TPA, alternatively EPA and DPA, and alternatively the compositions of the present invention comprise EPA, HPA and DPA.
  • the omega-3-pentaenoic acids in the compositions of the present invention comprise no more than 99.5% of a single omega-3-pentaenoic acid, alternatively no more than 99%; alternatively no more than 98.5%; alternatively no more than 98%; alternatively no more than 97.5%; alternatively no more than 96%; alternatively no more than 95%; alternatively no more than 94%; alternatively no more than 93%; alternatively no more than 92%; alternatively no more than 91 %; alternatively no more than 90%; alternatively no more than 88%; alternatively no more than 85%; alternatively no more than 80%; alternatively no more than 75%; alternatively no more than 70%; alternatively no more than 65%; alternatively no more than 60%; alternatively no more than 55%; alternatively no more than 50%; alternatively no more than 45%; alternatively no more than 40%; alternatively no more than 30%.
  • compositions of the present invention wherein at least 10%, alternatively at least 20%, alternatively at least 25%, alternatively at least 35%, alternatively at least 50%, alternatively at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, by weight of the fatty acids comprise omega-3-pentaenoic acids, salts, esters, or derivatives thereof.
  • compositions and methods comprise significant amounts of omega-3-pentaenoic acids or their glycerol or ethyl esters may be used in the methods of the present invention.
  • the compositions and methods comprise at least 100 mg omega-3-pentaenoic acids per day, alternatively at least 200mg omega-3-pentaenoic acids per day, alternatively at least 300mg omega-3-pentaenoic acids per day, alternatively at least 500mg omega-3- pentaenoic acids per day, alternatively at least 700mg omega-3-pentaenoic acids per day, alternatively at least 900mg omega-3-pentaenoic acids per day, alternatively at least 1000mg omega-3-pentaenoic acids per day, alternatively at least 1500mg omega-3-pentaenoic acids per day, alternatively at least 1900mg omega-3-pentaenoic acids per day, alternatively at least 2000mg omega-3- penta
  • the compositions provide a DHA as compared to the amount of omega-3-pentaenoic acids (N3-5enoicFA) such that the DHA:N3- 5enoicFA ratio is no more than 15:1 of DHA:N3-5enoicFA, alternatively no more than 12:1 of DHA:N3-5enoicFA, alternatively no more than 10:1 of DHA:N3-5enoicFA, alternatively no more than 8:1 of DHA:N3-5enoicFA, alternatively no more than 5:1 of DHA:N3-5enoicFA, alternatively no more than 3:1 of DHA:N3-5enoicFA, alternatively no more than 2:1 of DHA:N3-5enoicFA, alternatively no more than 1 :1 of DHA:N3-5enoicFA, alternatively no more than 1 :2 of DHA:N3-5enoicFA, alternatively no more than 1 :3 of DHA:N3-5enoicFA, alternatively no more than 1 :5 of
  • the compositions of the present invention comprise at least 0.01 % HPA of total fatty acids in the composition, alternatively at least 0.05% HPA, alternatively at least 0.10% HPA, alternatively at least 0.15% HPA, alternatively at least 0.2% HPA, alternatively at least 0.3% HPA, alternatively at least 0.4% HPA, alternatively at least 0.5% HPA, alternatively at least 0.75% HPA, alternatively at least 1 % HPA, alternatively at least 1.5% HPA, alternatively at least 2% HPA, alternatively at least 2.5% HPA, alternatively at least 3% HPA, alternatively at least 3.5% HPA, alternatively at least 4% HPA, alternatively at least 4.5% HPA, alternatively at least 5% HPA, alternatively at least 6% HPA, alternatively at least 7% HPA, alternatively the compositions of the present invention comprise at least 9% HPA of total fatty acids in the composition.
  • the compositions of the present invention comprise no more than 20% HPA of total fatty acids in the composition, alternatively no more than 15% HPA, alternatively no more than 12% HPA, alternatively no more than 10% HPA, alternatively no more than 8% HPA, alternatively no more than 7% HPA, alternatively no more than 6% HPA, alternatively no more than 5% HPA, alternatively no more than 4% HPA, alternatively no more than 3% HPA, alternatively no more than 2% HPA, alternatively no more than 1.5% HPA, alternatively the compositions of the present invention comprise at least 1 % HPA of total fatty acids in the composition. In some embodiments, the compositions of the present invention comprise 1 % to 20% HPA of the total fatty acids in the composition.
  • compositions of the present invention comprise about 1 % to about 6% HPA, alternatively about 2% to about 5% HPA, alternatively about 3% to about 4% HPA, relative to the total amount of fatty acids in the composition. In some embodiments, the compositions of the present invention comprise about 10 mg/g to about 50 mg/g HPA, alternatively about 15 mg/g to about 45 mg/g, alternatively about 20 mg/g to about 40 mg/g, alternatively about 25 mg/g to about 35 mg/g, alternatively about 30 mg/g HPA.
  • the present invention provides compositions and methods which comprise significant amounts of omega-3 heneicosapentaenoic acid (HPA) or its glycerol or ethyl esters.
  • the methods of treatment may provide to a subject in need thereof a dose of at least 10 mg HPA per day, alternatively at least 15 mg HPA per day, alternatively at least 20 mg HPA per day, alternatively at least 25 mg HPA per day, alternatively at least 30mg HPA per day, alternatively at least 40mg HPA per day, alternatively at least 50mg HPA per day, alternatively at least 60mg HPA per day, alternatively at least 70mg HPA per day, alternatively at least 80mg HPA per day, alternatively at least 90mg HPA per day, alternatively at least 100mg HPA per day, alternatively at least 120mg HPA per day, alternatively at least 150mg HPA per day, alternatively at least 160mg HPA per day, alternatively
  • the compositions of the present invention comprise no more than 10% omega-3 fatty acids that are not omega-3-pentaenoic acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.5%, alternatively no more than 1.25%, alternatively no more than 1 %, alternatively no more than 0.75%, alternatively no more than 0.5%, alternatively no more than 0.4%, alternatively no more than 0.3%, alternatively no more than 0.2%, alternatively the compositions of the present invention comprise no more than 0.1 % omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • the compositions comprise EPA and DPA in an EPA:DPA ratio between 99:1 and 1 :99 EPA:DPA, alternatively between 90:1 and 1 :90, alternatively between 60:1 and 1 :60, alternatively between 60:1 and 1 :20, alternatively between 60:1 and 1 :4, alternatively between 40:1 and 1 :20, alternatively between 30:1 and 1 :20, alternatively between 30:1 and 1 :10, alternatively between 30:1 and 1 :5, alternatively between 40:1 and 1 :4, alternatively between 30:1 and 1 :4, alternatively between 30:1 and 1 :2, alternatively between 30:1 and 1 :1 , alternatively between 30:1 and 2:1 , alternatively between 30:1 and 5:1 , alternatively between 20:1 and 1 :20, alternatively between 20:1 and 1 :10, alternatively between 20:1 and 1 :5, alternatively between 20:1 and 1 :2, alternatively
  • the ratio of EPA:DPA is greater than 1 :1 , preferably greater than 2:1 , and more preferably greater than 5:1. In some embodiments, the ratio of EPA:DPA is 1 :1 to 25:1 , preferably 5:1 to 20:1 , more preferably 8:1 to 15:1 , even more preferably 9:1 to 13:1 , even more most preferably about 10:1 to 1 1 :1 , and most preferably about 10:1.
  • the compositions comprise EPA in an amount between 55% and 95% relative to the total amount of fatty acids present in the composition, alternatively between 60% and 95%, alternatively between 65% and 95%, alternatively between 70% and 95%, alternatively between 75% and 95%, alternatively between 90% and 95%, alternatively between 80% and 95%, alternatively between 90% and 95%, alternatively between 55% and 90%, alternatively between 60% and 90%, alternatively between 65% and 90%, alternatively between 70% and 90%, alternatively between 75% and 90%, alternatively between 80% and 90%, alternatively between 85% and 90%, alternatively between 55% and 92%, alternatively between 60% and 92%, alternatively between 65% and 92%, alternatively between 70% and 92%, alternatively between 75% and 92%, alternatively between 80% and 92%, alternatively between 85% and 92%, alternatively between 55% and 93%, alternatively between 60% and 93%, alternatively between 65% and 93%, alternatively between 70% and 93%, alternatively between 75%
  • compositions comprise about 70% to about 95%, 80% to about 90%, alternatively about 81 % to about 88%, alternatively about 82% to about 88%, alternatively about 83% to about 87%, alternatively about 84% to about 86%, alternatively about 85% EPA relative to the total amount of fatty acids present in the composition.
  • the compositions comprise about 750 mg/g to about 950 mg/g, alternatively about 800 mg/g to about 900 mg/g, alternatively about 830 mg/g to about 870 mg/g, alternatively about 840 mg/g to about 870 mg/g, alternatively 845 mg/g to about 865 mg/g, alternatively 846 mg/g to about 860 mg/g, alternatively 847 mg/g to about 859 mg/g, alternatively about 848 mg/g to about 858 mg/g, alternatively about 849 mg/g to about 857 mg/g, alternatively about 850 mg/g to about 856 mg/g, alternatively about 851 mg/g to about 855 mg/g, alternatively about 852 mg/g to about 854 mg/g, alternatively about 853 mg/g EPA.
  • compositions of the present invention are preferably provided in a dose of between 100 mg and 10,000 mg/day, alternatively between 200 mg and 8,000 mg/day, alternatively between 300 mg and 6,000 mg/day, alternatively between 400 mg and 5,000 mg/day, alternatively between 500 mg and 4,000 mg/day.
  • compositions and methods of the present invention are provided in a dose of between about 1000 mg/day to about 5000 mg/day, alternatively about 1200 mg/day to about 3000 mg/day, alternatively about 1500 mg/day to about 2500 mg/day, alternatively 600 mg/day to about 1950 mg/day, alternatively about 1735 mg/day to about 1855 mg/day, alternatively about 1740 mg/day to about 1840 mg/day, alternatively about 1745 mg/day to about 1820 mg/day, alternatively about 1750 mg/day to about 1800 mg/day, alternatively about 1755 mg/day to about 1790 mg/day, alternatively about 1760 mg/day to about 1780 mg/day, alternatively about 1770 mg/day of EPA.
  • the compostiions of the present invention are provided in a dose of between about 2300 mg/day to about 3000 mg/day, alternatively about 2400 mg/day to about 2800 mg/day, alternatively about 2520 mg/day to about 2780 mg/day, alternatively about 2600 mg/day to about 2700 mg/day, alternatively about 2610 mg/day to about 2680 mg/day, alternatively about 2620 mg/day to about 2670 mg/day, alternatively about 2630 mg/day to about 2665 mg/day, alternatively about 2640 mg/day to about 2660 mg/day, alternatively about 2650 mg/day of EPA.
  • the compostions of the present invention are provided in a dose of between about 3200 mg/day to about 3900 mg/day, alternatively 3300 mg/day to about 3800 mg/day, alternatively 3360 mg/day to about 3710 mg/day, alternatively about 3400 mg/day to about 3700 mg/day, alternatively about 3450 mg/day to about 3650 mg/day, alternatively about 3500 mg/day to about 3600 mg/day, alternatively about 3530 mg/day to about 3580 mg/day, alternatively about 3540 mg/day to about 3560 mg/day, alternatively about 3550 mg/day of EPA.
  • compositions of the present invention are provided in a dose of between about about 1650 mg/day to about 2050 mg/day, alternatively about 1700 mg/day to about 2000 mg/day, alternatively about 1750 mg/day to about 1950 mg/day, alternatively about 1775 mg/day to about 1925 mg/day, alternatively about 1800 mg/day to about 1900 mg/day, alternatively about 1800 mg/day to about 2000 mg/day, alternatively about 1820 mg/day to about 1880 mg/day, alternatively about 1830 mg/day to about 1870 mg/day, alternatively about 1840 mg/day to about 1860 mg/day, alternatively about 1850 mg/day of EPA.
  • the compostions of the present invention are provided in a dose of between about about 2500 mg/day to about 3100 mg/day, alternatively about 2600 mg/day to about 2000 mg/day, alternatively about 2650 mg/day to about 2950 mg/day, alternatively about 2700 mg/day to about 2900 mg/day, alternatively about 2725 mg/day to about 2875 mg/day, alternatively about 2750 mg/day to about 2850 mg/day, alternatively about 2780 mg/day to about 2820 mg/day, alternatively about 2790 mg/day to about 2810 mg/day, alternatively about 2800 mg/day of EPA.
  • the compostions of the present invention are provided in a dose of between about 3300 mg/day to about 4000 mg/day, alternatively about 3400 mg/day to about 3900 mg/day, alternatively about 3500 mg/day to about 3900 mg/day, alternatively about 3550 mg/day to about 3850 mg/day, alternatively about 3600 mg/day to about 3800 mg/day, alternatively about 3650 mg/day to about 3750 mg/day, alternatively about 3680 mg/day to about 3725 mg/day, alternatively about 3690 mg/day to about 3710 mg/day, alternatively about 3700 mg/day of EPA.
  • compositions of the present invention are provided in a dose of between about 1500 mg/day to about 2500 mg/day, alternatively about 1750 mg/day to about 2300 mg/day, alternatively about 1800 mg/day to about 2200 mg/day, alternatively about 1900 mg/day to about 2100 mg/day, alternatively about 1950 mg/day to about 2050 mg/day, alternatively about 1975 mg/day to about 2025 mg/day, alternatively about 2000 mg/day of EPA.
  • compositions of the present invention are provided in a dose of between about 2500 mg/day to about 3500 mg/day, alternatively about 2700 mg/day to about 3300 mg/day alternatively about 2750 mg/day to about 3300 mg/day, alternatively about 2800 mg/day to about 3200 mg/day, alternatively about 2900 mg/day to about 3100 mg/day, alternatively about 2950 mg/day to about 3050 mg/day, alternatively about 2975 mg/day to about 3025 mg/day, alternatively about 3000 mg/day of EPA.
  • compositions of the present invention are provided in a dose of between about 3500 mg/day to about 4500 mg/day, alternatively about 3700 mg/day to about 4300 mg/day, alternatively about 3750 mg/day to about 4300 mg/day, alternatively about 3800 mg/day to about 4200 mg/day, alternatively about 3900 mg/day to about 4100 mg/day, alternatively about 3950 mg/day to about 4050 mg/day, alternatively about 3975 mg/day to about 4025 mg/day, alternatively about 4000 mg/day of EPA.
  • the compositions comprise DPA in an amount between 1 % and 99% relative to the total amount of fatty acids present in the composition, alternatively between 1 % and 95%, alternatively alternativelybetween 1 % and 90%, alternatively between 1 % and 85%, alternatively between 1 % and 80%, alternatively between 1 % and 75%, alternatively between 1 % and 70%, alternatively between 1 % and 65%, alternatively between 1 % and 60%, alternatively between 1 % and 55%, alternatively between 1 % and 50%, alternatively between 1 % and 45%, alternatively between 1 % and 40%, alternatively between 1 % and 35%, alternatively between 1 % and 30%, alternatively between 1 % and 25%, alternatively between 1 % and 20%, alternatively between 1 % and 15%, alternatively between 1 % and 10%, alternatively between 1 % and 5%, alternatively between 2% and 99%, alternatively between 2% and 95%, alternatively between 2% and 90%, alternatively between alternatively between 2% and 95%, alternatively between
  • compositions comprise docosapentaenoic acid (DPA) in an amount between about 5% to about 15%, alternatively about 6% to about 12%, alternatively about 7% to about 1 1 %, alternatively about 8% to about 10% relative to the total amount of fatty acids present in the composition.
  • DPA docosapentaenoic acid
  • the composition comprises at least about 4% or at least about 5% or at least about 6% or at least about 7% or at least about 8% or at least about 9% or at least about 10% or at least about 15% or at least about 20% or at least about 25% or at least about 30% or at least about 35% or at least about 40% or at least about 45% or at least about 50% or at least about 55% or at least about 60% or at least about 65% or at least about 70% or at least about 75% or at least about 80% or at least about 85% or at least about 90% or at least about 95% of docosapentaenoic acid (DPA).
  • DPA docosapentaenoic acid
  • compositions comprise docosapentaenoic acid (DPA) in an amount of about 60 mg/g to about 120 mg/g, alternatively about 70 mg/g to about 100 mg/g, 75 mg/g to about 90 mg/g, alternatively about 77 mg/g to about 85 mg/g, alternatively about 78 mg/g to about 84 mg/g, alternatively about 79 mg/g to about 83 mg/g, alternatively about 80 mg/g to about 82 mg/g, alternatively about 81 mg/g to about 82 mg/g.
  • DPA docosapentaenoic acid
  • compositions comprise docosapentaenoic acid (DPA) in an daily dosage amount of at least about 20 mg/day, alternatively at least about 25 mg/day, alternatively at least about 30 mg/day, alternatively at least about 40 mg/day, alternatively at least about 50 mg/day, alternatively at least about 60 mg/day alternatively, at least about 70 mg/day alternatively at least about 75 mg/day, alternatively at least about 80 mg/day, alternatively at least about 90 mg/day, alternatively at least about 100 mg/day, alternatively at least about 120 mg/day, alternatively at least about 150 mg/day, alternatively at least about 160 mg/day, alternatively at least about 180 mg/day, alternatively at least about 200 mg/day, alternatively at least about 250 mg/day, alternatively at least about 300 mg/day, alternatively at least about 350 mg/day, or alternatively at least about 400 mg/day, alternatively at least about 500 mg/day, alternatively at least about 600 mg/day, alternatively at least about 800 mg
  • DPA do
  • the composition comprises DPA in a daily dosage of about 120 mg/day to about 150 mg/day, alternatively about 150 mg/day to about 200 mg/day, alternatively about 200 mg/day to about 250 mg/day, alternatively about 250 mg/day to about 300 mg/day, alternatively about 300 mg/day to about 400 mg/day, alternatively about 400 mg/day to about 600 mg/day, alternatively about 600 mg/day to about 1000 mg/day.
  • the method of treatment provides a dose of at least about 1 mg/kg of docosapentaenoic acid (DPA) per day, alternatively about 2 mg/kg of DPA per day, alternatively about 3 mg/kg of DPA per day, alternatively about 4 mg/kg of DPA per day, alternatively about 6 mg/kg of DPA per day, alternatively about 8 mg/kg of DPA per day, alternatively about 10 mg/kg of DPA per day, alternatively about 20 mg/kg of DPA per day, alternatively about 30 mg/kg of DPA per day, and alternatively about 40 mg/kg of DPA per day, alternatively about 50 mg/kg of DPA per day, alternatively about 75 mg/kg of DPA per day, and alternatively about 100 mg/kg of DPA per day.
  • DPA docosapentaenoic acid
  • a relatively small amount of docosahexaenoic acid (DHA) as compared to EPA is present.
  • the compositions of the present invention comprise no more than 1 :1 of DHA:EPA, alternatively no more than 1 :2, alternatively no more than 1 :3, alternatively no more than 1 :3, alternatively no more than 1 :4, alternatively no more than 1 :5 of DHA:EPA, alternatively no more than 1 :6 of DHA:EPA, alternatively no more than 1 :7 of DHA:EPA, alternatively no more than 1 :8 of DHA:EPA, alternatively no more than 1 :9 of DHA:EPA, alternatively no more than 1 :10 of DHA:EPA, alternatively no more than 1 :12 of DHA:EPA, alternatively no more than 1 :15 of DHA:EPA, alternatively no more than 1 :20 of DHA:EPA, alternatively no more than 1 :25 of DHA:EPA, alternatively no more
  • DHA may be present in the compositions of this invention at a relative amount of ratio less than 1 % than the amount of EPA.
  • DHA docosahexaenoic acid
  • DHA may be present in the compositions of this invention at a DHA:EPA ratio of less than 1 :99.
  • a relatively small amount of docosahexaenoic acid (DHA) relative to the total amount of fatty acids present in the composition is present.
  • the compositions of the present invention comprise no more than 30% DHA, alternatively no more than 20% DHA, alternatively no more than 15% DHA, alternatively no more than 12% DHA, alternatively no more than 10% DHA, alternatively no more than 9% DHA, alternatively no more than 8% DHA, alternatively no more than 7% DHA, alternatively no more than 6% DHA, alternatively no more than 5% DHA, alternatively no more than 4% DHA, alternatively no more than 3% DHA, alternatively no more than 2% DHA, alternatively no more than 1 % DHA relative to the total amount of fatty acids present in the composition.
  • compositions and methods comprise less than 1500mg of DHA, alternatively less than 1200mg of DHA, alternatively less than 1000mg of DHA, alternatively less than 800mg of DHA, alternatively less than 700mg of DHA, alternatively less than 600mg of DHA, alternatively less than 500mg of DHA, alternatively less than 400mg of DHA, alternatively less than 350mg of DHA, alternatively less than 300mg of DHA, alternatively less than 250mg of DHA, alternatively less than 200mg of DHA alternatively less than 150mg of DHA, alternatively less than 120mg of DHA, alternatively less than 100 mg of DHA, alternatively less than 80 mg of DHA, alternatively less than 60 mg of DHA, alternatively less than 40 mg of DHA, alternatively less than 30 mg of DHA, alternatively less than 25 mg of DHA, alternatively less than 20 mg of DHA or its glycerol or ethyl esters as a totally daily dose.
  • the composition comprises about 5 mg/g to about 20 mg/g, alternatively about 8 mg/g to about 18 mg/g, alternatively about 9 mg/g to about 15 mg/g, alternatively about 10 mg/g to about 14 mg/g, alternatively about 1 1 mg/g to about 13 mg/g, alternatively about 12 mg/g to about 13 mg/g of docosahexaenoic acid (DHA).
  • DHA docosahexaenoic acid
  • the ratio of EPA:HPA is about 1500:1 to 25:1 , alternatively 1000:1 to 50:1 , alternatively 800:1 to 60:1 , alternatively 500:1 to 60:1 , alternatively 250:1 to 75:1 , and alternatively 100:1 to 80:1. In some preferred embodiments, the ratio of EPA:HPA is about 85:1. In some preferred embodiments, the ratio of EPA:HPA is about 30:1 .
  • the ratio of DPA:HPA is about 250:1 to 1 :1 , alternatively 200:1 to 2:1 , alternatively 150:1 to 3:1 , alternatively 100:1 to 4:1 , alternatively 50:1 to 5:1 , alternatively 25:1 to 6:1 , and alternatively 10:1 to 7:1. In some preferred embodiments, the ratio of DPA:HPA is about 8:1. In some embodiments, the ratio of DPA:HPA is about 3:0.
  • compositions of the present invention comprise no more than 15:1 of DHA:DPA, alternatively no more than 12:1 of DHA:DPA, alternatively no more than 10:1 of DHA:DPA, alternatively no more than 8:1 of DHA:DPA, alternatively no more than 5:1 of DHA:DPA, alternatively no more than 4:1 of DHA:DPA, alternatively no more than 3:1 of DHA:DPA, alternatively no more than 2:1 of DHA:DPA, alternatively no more than 1 :1 of DHA:DPA, alternatively no more than 1 :2 of DHA:DPA, alternatively no more than 1 :3 of DHA:DPA, alternatively no more than 1 :4 of DHA:DPA, alternatively no more than 1 :5 of DHA:DPA, alternatively no more than 1 :6 of DHA:DPA, alternatively no more than 1 :
  • compositions of the present invention comprise no more than 15:1 of DHA:HPA, alternatively no more than 12:1 of DHA:HPA, alternatively no more than 10:1 of DHA:HPA, alternatively no more than 8:1 of DHA:HPA, alternatively no more than 5:1 of DHA:HPA, alternatively no more than 3:1 of DHA:HPA, alternatively no more than 2:1 of DHA:HPA, alternatively no more than 1 :1 of DHA:HPA, alternatively no more than 1 :2 of DHA:HPA, alternatively no more than 1 :3 of DHA:HPA, alternatively no more than 1 :5 of DHA:HPA, alternatively no more than 1 :8 of DHA:HPA, alternatively no more than 1 :10 of DHA:HPA, alternatively no more than 1 :15 of DHA:HPA, alternatively no more than
  • compositions of the present invention comprise no more than 10% omega-6 fatty acids relative to the total amount of fatty acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1.5%, alternatively no more than 1.2%, alternatively no more than 1 %, alternatively no more than 0.5% omega-6 fatty acids versus the total amount of fatty acids comprised by the compositions of the present invention.
  • Omega-6 fatty acids include, but are not limited to: linoleic acid (LA; C18:2- n6); gamma-linoleic acid (GLA; C18:3-n6); eicosadienoic acid (C20:2-n6); dihomo- gamma-linoleic acid (DGLA; C20:3-n6); arachiconic acid (ARA; C20:4-n6); and omega-6 docosapentaenoic acid (DPA; C22:5-n6).
  • LA linoleic acid
  • GLA gamma-linoleic acid
  • C20:2-n6 eicosadienoic acid
  • DGLA dihomo- gamma-linoleic acid
  • ARA arachiconic acid
  • DPA omega-6 docosapentaenoic acid
  • compositions of the present invention comprise no more than 10% omega-6 fatty acids relative to the total amount of omega-3 fatty acids plus omega-6 fatty acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1 .7%, alternatively no more than 1 .5%, alternatively no more than 1.2%, alternatively no more than 1 %, alternatively no more than 0.5% omega-6 fatty acids versus the total amount of omega-3 fatty acids plus omega-6 fatty acids comprised by the compositions of the present invention.
  • compositions of the present invention comprise no more than 8% arachidonic acid (ARA; C20:4-n6) relative to the total amount of omega-3 fatty acids plus omega-6 fatty acids, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1.5%, alternatively no more than 1 .2%, alternatively no more than 1 %, alternatively no more than 0.5% arachidonic acid (ARA; C20:4-n6) versus the total amount of omega-3 fatty acids plus omega-6 fatty acids comprised by the compositions of the present invention.
  • ARA arachidonic acid
  • a relatively small amount of omega-3 fatty acids in aggregate other than EPA, ETA, HPA and DPA (alternatively indicated as non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids in aggregate) relative to the total amount of fatty acids present in the composition is present.
  • compositions of the present invention comprise no more than 20% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 15% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 12% non-EPA, non-ETA, non-HPA and non-DPA omega- 3 fatty acids, alternatively no more than 10% non-EPA, non-ETA, non-HPA and non- DPA omega-3 fatty acids, alternatively no more than 8% non-EPA, non-ETA, non- HPA and non-DPA omega-3 fatty acids, alternatively no more than 7% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 6% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 5% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 5% non-EPA,
  • a relatively small amount of the sum of ALA, SDA and DHA relative to the total amount of fatty acids present in the composition is present, while at the same time large amounts of the sum of EPA, DPA-n3, HPA and ETA are present.
  • compositions of the present invention comprise no more than 20% of the sum of ALA, SDA and DHA, alternatively no more than 15% of the sum of ALA, SDA and DHA, alternatively no more than 12% of the sum of ALA, SDA and DHA, alternatively no more than 10% of the sum of ALA, SDA and DHA, alternatively no more than 8% of the sum of ALA, SDA and DHA, alternatively no more than 7% of the sum of ALA, SDA and DHA, alternatively no more than 6% of the sum of ALA, SDA and DHA, alternatively no more than 5% of the sum of ALA, SDA and DHA, alternatively no more than 4% of the sum of ALA, SDA and DHA, alternatively no more than 3% of the sum of ALA, SDA and DHA, alternatively no more than 2% of the sum of ALA, SDA and DHA, alternatively no more than 1 % of the sum of ALA, SDA and DHA relative to the total amount of
  • compositions of the present invention comprise no more than 8% arachidonic acid (ARA; C20:4-n6) relative to the total amount of fatty acids, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1 .5%, alternatively no more than 1 .2%, alternatively no more than 1 %, alternatively no more than 0.5% arachidonic acid (ARA; C20:4-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
  • ARA arachidonic acid
  • compositions of the present invention comprise no more than 2.5% arachidonic acid (ARA; C20:4-n6), no more than 0.4% omega-6- docosapentaenoic acid (DPA; C22:5-n6) and no more than 0.2% gamma-linoleic acid (GLA; C18:3-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
  • ARA arachidonic acid
  • DPA omega-6- docosapentaenoic acid
  • GLA gamma-linoleic acid
  • fatty acid compositions comprising no more than 2.5% arachidonic acid (ARA; C20:4-n6), no more than 0.3% omega-6 docosapentaenoic acid (DPA; C22:5-n6) and no more than 0.1 % gamma-linoleic acid (GLA; C18:3-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
  • ARA arachidonic acid
  • DPA docosapentaenoic acid
  • GLA gamma-linoleic acid
  • the composition of the present invention further comprises TPA at concentration of at least 0.05%.
  • the TPA concentration is about 0.01 % to about 5%, alternatively about 0.05% to about 2%, alternatively about 0.1 % to about 1 %, alternatively about 0.2% to about 0.8%, alternatively about 0.4% to about 0.6%, alternatively about 0.5%.
  • compositions of the present invention may also be taken as a general nutritional supplement.
  • the active ingredient of the formulations of the present invention consists essentially wholly of the EPA and DPA or precursors thereof (ethyl ester, triglyceride, or any other pharmaceutically acceptable salt or derivative thereof).
  • no large amounts preferably less than 15%, alternatively less than 12%, alternatively less than 10%, alternatively less than 9%, alternatively less than 8%, alternatively less than 7%, alternatively less than 6%, alternatively less than 5%, alternatively less than 4%, alternatively less than 3%, alternatively less than 2%, alternatively less than 1 %, alternatively less than 0.5%, alternatively less than 0.25%
  • any other fatty acids are present.
  • the active ingredient of the formulations of the present invention consists essentially wholly of omega-3-pentaenoic acids or precursors thereof (ethyl ester, triglyceride, or any other pharmaceutically acceptable salt or derivative thereof).
  • no large amounts preferably less than 15%, alternatively less than 12%, alternatively less than 10%, alternatively less than 9%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 3%, alternatively less than 2%, alternatively less than 1 %, alternatively less than 0.5%, alternatively less than 0.25%
  • any other fatty acids are present.
  • the fatty acid percentage is determined on a weight/weight, mol/mol, or chromatography area percent basis relative to all fatty acids present in the composition as determined by methods such as disclosed in the European Pharmacopeia monograph for omega-3 fatty acid concentrates, European Pharmacopeia monograph for omega-3-acid ethyl esters 90%, or European Pharmacopeia monograph method 2.4.29, USP monograph for fish oil dietary supplements, USP 35 omega-3-acid ethyl esters (LOVAZA®) monograph, or any essentially equivalent methods (whether by gas chromatography, HPLC, FPLC or any other chromatographic method).
  • the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of fatty acid ethyl esters as percentage of all fatty acid ethyl esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: free fatty acids; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • phospholipids such as phosphatidylserine or phosphatidylcholine
  • polysorbates such as Tween 80, Tween 20, or polysorbate 40.
  • the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of free fatty acid as percentage of all free fatty acids present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: fatty acid ethyl esters; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • fatty acids present for instance: fatty acid ethyl esters; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of glycerol fatty acid ester as percentage of all glycerol fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • fatty acids present for instance: fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as di- or tri-fatty acid esters with glycerol as percentage of all glycerol di- and tri-fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: glycerol-mono-fatty acid esters; fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • phospholipids such as phosphatidylserine or phosphatidylcholine
  • polysorbates such as Tween 80, Tween 20, or polysorbate 40.
  • the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a tri-fatty acid esters with glycerol as percentage of all glycerol tri-fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: mono- and di-fatty acid esters of glycerol; fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
  • phospholipids such as phosphatidylserine or phosphatidylcholine
  • polysorbates such as Tween 80, Tween 20, or polysorbate 40.
  • the EPA, HPA, DPA, or omega-3-pentaenoic acids may be derived from any appropriate source including plant seed oils, microbial oils from algae or fungal or marine oils from fish or other marine animals. Certain species are a particular good source of oils containing DPA, for example seal oil. They may be used in the form of the natural oil, if that oil meets the required purity requirements of the present invention, or may be purified to give products containing the fatty acid composition of the present invention.
  • compositions of the present invention may be produced through a range of the methods.
  • Such methods may include: distillation, including short path distillation; urea precipitation; enzymatic conversion concentration; conventional chromatography; HPLC/FPLC; supercritical carbondioxide extraction; supercritical carbondioxide chromatography; simulated moving bed chromatography; supercritical carbondioxide simulated moving bed chromatography; or chemical conversion methods such as iodolactonization.
  • distillation including short path distillation; urea precipitation; enzymatic conversion concentration; conventional chromatography; HPLC/FPLC; supercritical carbondioxide extraction; supercritical carbondioxide chromatography; simulated moving bed chromatography; supercritical carbondioxide simulated moving bed chromatography; or chemical conversion methods such as iodolactonization.
  • Such methods are generally known to those skilled in the art of purifying and isolating omega-3 fatty acids.
  • the omega-3 fatty acid concentration/purification process is initiated by esterifying the fatty acids comprised by the marine oil raw material (such as crude fish oil) with ethanol (to form fatty acid ethyl esters) in order to separate omega-3 fatty acids from other fatty acids covalently bound together in the natural triglyceride molecules of the source oil. Subsequently, the material may be distilled once or several times to achieve omega-3-acid ethyl ester concentrations above 60%-70%. Alternatively, enzymatic concentration, urea precipitation or supercritical extraction may be used alone or in conjunction with distillation to reach omega-3 levels above 70%-90%.
  • chromatography In order to prepare a highly pure concentrate of a single omega-3 fatty acid, methods such as chromatography, supercritical chromatography, simulated moving bed chromatography, supercritical simulated moving bed chromatography, or chemical conversion methods such as iodolactolization are typically most practical to reach levels above 50%, alternatively above 60%, alternatively above 70%, alternatively above 80%, alternatively above 90%, alternatively above 95%, of a single omega-3 fatty acid such as ETA, EPA, HPA, DPA, TPA, or DHA.
  • a single omega-3 fatty acid such as ETA, EPA, HPA, DPA, TPA, or DHA.
  • EPA is relatively abundant in fish oils or other marine oils and can be relatively easy obtained through the application of concentration and purification technologies from such fish or marine oils.
  • DPA and HPA are present at much lower concentrations.
  • DPA or HPA may be concentrated and purified from fish or other marine oils according to the methods referred to above, either alone or DPA combined with EPA and/or HPA.
  • the DPA or HPA may be chemically prepared from a high purity EPA concentrate by elongation of the EPA fatty-acid chain with two or one hydrogen- saturated carbons (C2-elongation or C1 -elongation) on the carboxyl side of the molecule (for instance with a method similar to or alternate methods with equivalent results such as described by Kuklev DV and Smith WL in Chem Phys Lipids, 2006; 144(2): 172-177).
  • a high purity EPA concentrate may be partially converted to DPA (or HPA) using a method for C2-elongation (or C1 -elongation) of EPA similar to those described above, thus directly yielding compositions of the present invention or intermediates therefore.
  • oils containing one or more of the desired fatty acids may be blended to give the desirable relative amounts of EPA, DPA, HPA, DHA, TPA, other omega-3 fatty acids and omega-6 fatty acids to obtain the compositions of the present invention described in detail above.
  • Fish oils may also contain by-products and contaminants such as pesticides, chlorinated or brominated hydrocarbons, heavy metals, cholesterol and vitamins. During the production of the concentrate, the concentrations of these components are significantly reduced compared to untreated fish oils. Such reduction is inherent due to the nature of purification methods and their ability to concentrate of several or specific omega-3 fatty acids, thus removing other compounds.
  • Triglycerides comprising more than 60% of the omega-3 fatty acids in the composition may be produced from ethyl esters and glycerol by well known, published, or alternative chemical synthetic or enzymatic procedures.
  • the free acids may be produced from ethyl esters by well known hydrolization or saponification procedures. Methods for converting ethyl esters to triglycerides, free fatty acids, and other molecular forms comprising fatty acids, are generally known to those skilled in the art chemically or enzymatically converting omega-3 fatty acids from one form to another.
  • compositions of the present invention have improved pharmacological features as demonstrated by improved bioavailability in a mammal of EPA, HPA, DPA, DHA, EPA+DHA, EPA+DPA or EPA+HPA+DPA combined, total omega-3-pentaenoic acids, or of total omega-3 fatty acids.
  • Key parameters for determining bioavailability are maximum concentration of a therapeutic compound or a metabolite thereof (Cmax); the time from administration to maximum concentration (Tmax); and the area under the concentration curve over time (AUC). Such parameters may be determined under single dose or multiple dose administration regimens. Methods to determine comparative bioavailability in mammals are generally known to those skilled in the art.
  • Meal conditions during administration to a subject of omega-3 fatty acid compositions or omega-3 fatty acid formulations can be of special significance for absorption and bioavailability of omega-3 fatty acids.
  • the meal conditions typically considered are: fasting (no food at all prior for 8-12 hours prior to administration and 2-3 hours post administration of the treatment); a low fat meat (a meal typically containing less than 25 gram of fat [350-600 Kcal] consumed just before or after the administration of the treatment; typically within a 15-30 minute range); or a high fat meat (a meal containing 40 gram to 75 gram of fat [700-1000 Kcal] consumed just before or after the administration of the treatment; typically within a 15-30 minute range).
  • compositions of the present invention are more rapidly absorbed as measured by the time to reach the maximum concentration (Tmax) in blood, serum or plasma of EPA, DPA, DHA , EPA+DPA, EPA+DHA, total omega-3-pentaenoic acids, or total omega-3 fatty acids.
  • Tmax under high fat meal administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
  • Tmax under low fat meal administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
  • Tmax under fasting administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
  • Tmax for EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids are equal or less than than Tmax for AMR101 for EPA, DPA, DHA , EPA+DPA, EPA+DHA, total omega-3- pentaenoic acids, or total omega-3 fatty acids under high fat meat, low fat meal, and fasting administration conditions.
  • Tmax for EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids are less than Tmax for AMR101 for EPA+DHA and to EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids under either low fat meal, fasting, or both administration conditions.
  • the improved bioavailability features described above are apparent upon single dose administration, while in other embodiments the improved bioavailability features described above are apparent after multiple dose administration of formulations according to the present invention as compared to referenced comparator products above or substantial equivalent forms thereof.
  • compositions of the present invention are more potent and effective than other omega-3 compositions known in the prior art (such as LOVAZA®, EPANOVATM or VASCEPA®).
  • the formulation may be a single daily dose preparation to give in one dose the above intakes, or may be in convenient divided doses, for example, a daily dose formed of two to four soft gelatin or other dosage forms, each containing 300-1500 mg of EPA, EPA+DPA, EPA+DPA+HPA, or omega-3-pentaenoic acids in any form embodied in the present invention.
  • Flavourants or emulsifiers may be included, for instance, to make the preparation palatable. Other conventional additives, diluents and excipients may be present.
  • the preparation for ingestion may be in the form of a capsule, a dry powder, a tablet, a solution, an oil, an emulsion or any other appropriate form.
  • the capsules may be hard or soft gelatin capsules, agar capsules, or any other appropriate capsule.
  • the omega-3 fatty acid composition optionally includes chemical antioxidants, such as alpha tocopherol, which are administered in pure form or suspended in a vegetable oil, such as soybean oil or corn oil.
  • chemical antioxidants such as alpha tocopherol
  • the blended fatty acid compositions may then be incorporated into any appropriate dosage form for oral, enteral, parenteral, rectal, vaginal, dermal or other route of administration.
  • Soft or hard gelatin capsules, flavoured oil blends, emulsifiers or other liquid forms, and microencapsulate powders or other dry form vehicles are all appropriate ways of administering the products.
  • the formulated final drug product containing the omega-3 fatty acid composition may be administered to a mammal or patient in need thereof in a capsule, a tablet, a powder that can be dispersed in a beverage, or another solid oral dosage form, a liquid, a soft gel capsule or other convenient dosage form such as oral liquid in a capsule, as known in the art.
  • the capsule comprises a hard gelatin.
  • the combination product may also be contained in a liquid suitable for injection or infusion.
  • Example pharmaceutical grade finished dosage forms (a) Soft or hard gelatin capsules each containing 500 mg or 1000 mg of a mix 20 parts of EPA as a free fatty acid to 1 parts of DPA as a free fatty acid; (b) As in (a) but where the EPA and DPA free fatty acids are replaced with the fatty acids in any other appropriate bioassimilable form such as the ethyl esters; (c) As in (a)-(b) but where the material is in the form of a microencapsulated powder which can be used as a powder or compressed into tablets.
  • Such powders may be prepared by a variety of technologies known to those skilled in the art; (d) As in (a)-(b) but where the formulation is a liquid or emulsion, appropriately flavoured for palatable oral administration; (e) As in (a)-(b) but where the material is formulated into a pharmaceutically acceptable vehicle appropriate for topical application such as a cream or ointment.
  • the omega-3 compositions of the present invention may also be administered with a combination of one or more non-active pharmaceutical ingredients (also known generally herein as "excipients").
  • Non-active ingredients serve to solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and fashion the active ingredients into an applicable and efficacious preparation that is safe, convenient, and otherwise acceptable for use.
  • the non-active ingredients may include colloidal silicon dioxide, crospovidone, lactose monohydrate, lecithin, microcrystalline cellulose, polyvinyl alcohol, povidone, sodium lauryl sulfate, sodium stearyl fumarate, talc, titanium dioxide and xanthum gum.
  • pharmaceutically acceptable vehicle includes any of the following: a solution where the first API and optional other ingredients are wholly dissolved in a solubilizer (e.g., a pharmaceutically acceptable solvent or mixture of solvents), wherein the solution remains in clear liquid form at about room temperature; a suspension; an oil; or a semi-solid, wherein the first API and optionally other ingredients are dissolved wholly or partially in a solubilizer (an emulsion, cream, etc.).
  • a solubilizer e.g., a pharmaceutically acceptable solvent or mixture of solvents
  • a "pharmaceutical grade finished dosage form” as used herein may be construed as a unit dose form suitable for administration to, for example, human or animal subjects, and having content uniformity acceptable to regulatory authorities.
  • a pharmaceutical grade finished dosage form should have an amount of API within the range of 85% to 1 15% of the desired dosage and an RSD less than or equal to 6.0%.
  • a pharmaceutical grade finished dosage form must be stable (i.e., have a "shelf life") for a pharmaceutically acceptable duration of time, preferably at least six months, alternatively at least one year.or at least two years, when stored at room temperature (about 23 degree Celcius to 27 degree Celcius , preferably about 25 degree Celcius) and 60% relative humidity.
  • stability is determined by physical appearance and/or chemical modification of the ingredients, in accordance with standards well- known in the pharmaceutical arts, including those documented in ICH guidelines.
  • the omega-3 fatty acid dosage form optionally includes chemical antioxidants, such as alpha tocopherol, oils, such as soybean oil and partially hydrogenated vegetable oil, and lubricants such as fractionated coconut oil, lecithin and a mixture of the same.
  • chemical antioxidants such as alpha tocopherol, oils, such as soybean oil and partially hydrogenated vegetable oil
  • lubricants such as fractionated coconut oil, lecithin and a mixture of the same.
  • compositions of the present invention may be used for the treatment of patients by administering an effective amount of such compositions to a subject in need thereof, such as a subject prone to or afflicted with a disease or condition or in need of treatment for a disease or condition.
  • the present invention provides methods of treating, preventing, and reducing the symptoms, pathology or events associated with a disease or condition comprising administration of any of the compositions of the present invention.
  • the present invention provides methods of treating, preventing, reducing the occurrence of, and reducing symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease, or related conditions.
  • CHD coronary heart disease
  • vascular disease vascular disease
  • atherosclerotic disease or related conditions.
  • the present invention also provides methods of treating, preventing, reducing the occurrence of, and reducing the symptoms, pathology or events associated with vascular-related diseases or conditions.
  • vascular diseases and conditions include, but are not limited to: atherosclerosis, atherosclerosis associated with hypercholesterolemia, hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, peripheral artery disease (PAD), heart failure, cardiac arrhythmias, blood coagulatory conditions associated with cardiac arrhythmias, hypertension, coagulation related disorders (including but not limited to post-surgical deep vein thrombosis or other high risk thrombosis conditions), nephropathy and other kidney diseases, renal impairment, retinopathy, cognitive impairment, dementia (including but not limited to ischemic dementia and vascular dementia), and metabolic syndrome.
  • compositions of the present invention may be used for the treatment of patients by administering an effective amount of such compositions to a subject or a subject in need thereof, such as a subject prone to or afflicted with a vascular/cardiovascular disease or condition, a subject at risk of vascular/cardiovascular events, or a subject in need of treatment for a vascular/cardiovascular disease or condition.
  • the present invention provides for the prevention of death (including all cause mortality, cardiovascular mortality, and cardiac death); the treatment and/or prevention of cardiac events, cardiovascular events and/or vascular events and/or symptoms. In some embodiments, the present invention also provides for the reduction of number or frequency of such events, as well as a reduction or amelioration of symptoms associated with such events.
  • Vascular, cardiovascular and/or cardiac events may include, but are not limited to: death due to cardiovascular event (including cardiovascular death and cardiac death), sudden cardiac death, myocardial infarction (fatal or non-fatal), ischemic cardiac attack, ischemic attack, angina, stroke, transient ischemic cerebral attack, thrombosis, deep vein thrombosis, pulmonary embolism, coronary revascularization, coronary revascularization with stent placement, carotid artery revascularization, carotid artery revascularization with stent placement, peripheral artery revascularization, peripheral artery revascularization with stent placement, major coronary event, coronary artery bypass grafting, other blood vessel grafting, treatment of aneurism, plaque rupture, and hospitalization due to cardiovascular event (including angina, acute angina and unstable angina).
  • cardiovascular event including angina, acute angina and unstable angina.
  • Cardiovascular and/or cardiac events may also include other events deemed to fall in such category by those skilled in the art.
  • Study endpoints may comprise individual events or a composite of several of the events described directly above (for the latter the term Major Adverse Cardiovascular Event or MACE is often used).
  • the present invention provides methods of retarding the atherosclerotic disease process or improves the vascular healing process in response to presence of atherogenic disease.
  • Such retardation or healing may be demonstrated by reduced stenosis and/or restenosis at specific vascular sites over time, reduced or lesser increase in intima-media thickness (IMT) of the arterial wall over time, larger lumen size and/or larger vascular diameter at vascular sites with stenosis or clot built-up over time.
  • IMT intima-media thickness
  • Such retardation or healing may be determined by intravascular ultrasound (IVUS), radiographic, echocardiographic, radiologic, noninvasive ultrasound, tomography, magnetic resonance interference (MRI), or other acceptable methods.
  • IVUS intravascular ultrasound
  • MRI magnetic resonance interference
  • such retardation or improved healing may be demonstrated by the vascular wall composition, such as a reduced foam cell presence or fibrillated tissue in the vessel wall.
  • such improved vascular healing is demonstrated by improved inflammatory markers in the vascular wall or specific types of staining of vascular tissue.
  • compositions of the present invention may differentially alter the ratio between blood platelets and fragments thereof (also known as platelet microparticles). Such fragments may be evaluated as a whole or examined and described as fragment sub-categories. [0109] In some embodiments, the compositions of the present invention may differentially alter the surface charge of blood platelets and fragments thereof, either in resting state (non-activated platelets) or activated stage.
  • compositions of the present invention may affect the coagulatory cascade and differentially alter coagulation or bleeding times or platelet aggregation times and density.
  • compositions of the present invention may be useful for any subjects and they may be especially useful in certain patient populations, including but not limited to the following: subjects having receiving treatment for or in need of treatment for hypertriglyceridemia, hypercholesterolemia, Frederickson dyslipidemia, and other comorbidities.
  • the present invention provides for methods of treatment of subjects with no previous cardiovascular events, or subjects with one or more previous cardiovascular events.
  • the subjects to be treated with or administered the compositions of the present invention are selected based on their dyslipidemic profile.
  • Subjects may be selected for treatment/administration from the following categories: hypertriglyceridemia (such as TG ⁇ 750mg/dL, TG>500mg/dL, TG>200mg/dL, TG>150mg/dL, TG500-2000mg/dL, TG500- 1500mg/dL, TG750-2000mg/dl_, TG750-1500mg/dL, TG200-499mg/dL, TG300- 499mg/dL, TG350-499mg/dl_, TG300-750mg/dl_, TG300-700mg/dL, TG200- 499mg/dL, or TG150-199mg/dL); hypercholesterolemia (such as LDL-C ⁇ 70mg/dL, LDL-C>70mg/dL, LDL-C>100mg/dL, LDL-C>130/dl_, LDL-C>160mg
  • the subjects to be treated with or administered the compositions of the present invention are selected based on the presence of certain comorbidities.
  • comorbidities may include, but are not limited to the following: renal disease, nephropathy, IgA nephropathy, renal impairment, renal failure (also kidney failure or renal insufficiency), renal insufficiency requiring dialysis, renal insufficiency without dialysis treatment, chronic analgesic nephritis, polycystic kidney disease, proteinuria, hypertension, thrombotic microangiopathy, renal failure (acute renal failure, chronic renal failure), uremic pericarditis, uremia, renal artery stenosis, renal ischemia, hypertensive nephropathy, renovascular hypertension, renal osteodystrophy, nephroptosis, renal cortical necrosis, glomerulitis, metabolic syndrome, diabetes, or pre-diabetes.
  • the methods of administering the compositions of the present invention are useful in subjects having cardiopathy, coronary ischemia, cardiac decompensation, or diabetic pathology with cardiopathy, and subjects with previous myocardial infarction, stroke, recent myocardial infarction (post-MI), Acute Coronary Syndrome (ACS), ACS without ST-segment elevation (NSTEMI), ACS with ST-segment elevation (STEMI), or any other major cardiovascular event.
  • the compositions of the present invention may reduce the reoccurrence of such cardiovascular events.
  • treatment with the compositions of the present invention results in clinical improvement of such comorbidities.
  • administration with the compositions of the present invention may reduce the time necessary to achieve clinical improvement and/or attain treatment goals.
  • the administration of compositions can result in clinical improvements in clinical markers, including, but not limited to: glomerular filtration rate, serum creatinine, serum urea, serum phosphate levels, serum potassium levels, systolic or diastolic blood pressure, progression to dialysis, progression to renal failure, progression to need for renal transplant, fasting serum glucose levels, postprandial serum glucose levels, serum fructosamine levels, therapeutic insulin utilization, progression to diabetes, hypo-glucose events, hyper- glucose events, or hemoglobin A1 C.
  • compositions of the present invention may be co-administered with one or more other therapeutic agents.
  • clinical benefits resulting from the administration or treatment of subjects with the compositions of the present invention may be improved with concomitant use or in combination with other therapeutic agents.
  • Examples of such concomitant or fixed combination treatments may include coadministration with one or more of the following: an HMG-CoA reductase inhibitor ("statin”), an anti-platelet agent (such as aspirin or clopidogrel), an anti-coagulant (such as warfarin) an antihypertensive (such as a diuretic, beta- blocker, calcium channel blocker, ACE-inhibitor, angiotensin II receptor (ARB) antagonist), or other treatments for cardiovascular diseases.
  • an HMG-CoA reductase inhibitor such as aspirin or clopidogrel
  • an anti-coagulant such as warfarin
  • an antihypertensive such as a diuretic, beta- blocker, calcium channel blocker, ACE-inhibitor, angiotensin II receptor (ARB) antagonist
  • the present invention also provides pharmaceutical compositions, for example, a unit dosage, comprising one or more HMG-CoA reductase inhibitors ("statins") and an omega-3 fatty acid composition of the present invention.
  • statins HMG-CoA reductase inhibitors
  • the present invention provides a fixed dose combination product comprising both a statin and the composition of the present invention.
  • the present invention may incorporate currently known or future known statins in an amount generally recognized as safe and effective. There are currently seven statins that are widely available: atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, pravastatin, and simvastatin. An eighth statin, cerivastatin, has been removed from the U.S. market at the time of this writing.
  • cerivastatin may be used in conjunction with some embodiments of the present invention if cerivastatin is ultimately determined to be safe and effective in certain treatment regimens.
  • Such statins are typically used at their common daily doses, which include, but are not limited to lovastatin 10mg, 20mg, 40mg; pravastatin 10mg, 20mg, 40mg, 80mg; simvastatin 5mg, 10mg, 20mg, 40mg, 80mg; fluvastatin 20mg, 40mg, 80mg; atorvastatin 10mg, 20mg, 40mg, 80mg; rosuvastatin 5mg, 10mg, 20mg, 40mg; and pitavastatin 1 mg, 2mg, 4mg, 8mg.
  • statins are dose dependent, i.e., the higher the dose, the greater the therapeutic affect.
  • the effect of each statin is different, and therefore the level of therapeutic effect of one statin cannot be necessarily be directly correlated to the level of therapeutic effects of other statins.
  • bioavailability varies widely among the statins. Specifically, it has been shown that simvastatin is less than 5% bioavailable, while fluvastatin is approximately 24% bioavailable. Statins are absorbed at rates ranging from about 30% with lovastatin to 98% with fluvastatin. First-pass metabolism occurs in all statins except pravastatin.
  • Pravastatin is also the least protein-bound of the statins (about 50%), compared with the others, which are more than 90% protein-bound. Accordingly, the statins possess distinct properties from one another.
  • the combination products of this invention involving each statin or a plurality of statins are also distinct.
  • the method of treatment may combine the administration of one or more statins at its common dose or an alternative dose with the composition of the present invention
  • a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 98:2 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate) converted to ethyl ester, respectively.
  • MEGAPEX E90D00EE 90% EPA ethyl ester,
  • MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
  • the resulting novel composition comprises 89.10% EPA, 1.95% DPA, 0.19% HPA, 91.24% omega-3-pentaenoic acids, less than 0.01 % DHA, 91.24% omega-3-pentaenoic acids, 93.09% total omega-3 fatty acids, 3.15% ARA and 3. 57% omega-6 fatty acids (all Area%).
  • a composition according to the present prevention is prepared by mixing and homogenizing in a ratio of 96:4 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate), converted to ethyl ester, respectively.
  • MEGAPEX E90D00EE 90% EPA ethyl ester,
  • MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
  • MAXOMEGA DPA95 FFA
  • the resulting novel composition comprises 87.28% EPA, 3.89% DPA, 0.18% HPA, 91.35% omega-3-pentaenoic acids, less than 0.01 % DHA, 93.17% total omega-3 fatty acids and 3.49% omega-6 fatty acids (all Area%).
  • a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 94:6 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate) converted to ethyl ester, respectively.
  • MEGAPEX E90D00EE 90% EPA ethyl ester,
  • MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
  • the resulting novel composition comprises 85.46% EPA, 5.84% DPA, 0.18% HPA, 91.48% omega-3-pentaenoic acids, less than 0.01 % DHA, 93.26% total omega-3 fatty acids, 3.02% ARA, and 3.42% omega- 6 fatty acids (all Area%).
  • a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 75:25 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate, converted to ethyl ester, respectively.
  • MEGAPEX E90D00EE 90% EPA ethyl ester,
  • MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate, converted to ethyl ester, respectively.
  • These intermediates were prepared and commercially offered for sale by Chemport Korea (MEGAPEX) and Equateq Ltd from Scotland, UK (MAXOMEGA).
  • the relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 4 below.
  • the resulting novel composition comprises 68.10% EPA, 24.32% DPA, 0.19% HPA, 92.65% omega-3-pentaenoic acids, less than 0.01 % DHA, 94.07% total omega-3 fatty acids, 2.41 % ARA and 2.73% omega-6 fatty acids (all Area%).
  • a composition according to the present invention isprepared by mixing and homogenizing in a ratio of 60:40 the intermediates KD-PharmaKD-PUR 900EE and MAXOMEGA DPA95 FFA converted to ethyl ester, respectively. These intermediates were prepared and commercially offered for sale by KD-Pharma Germany (KD-Pharma) and Equateq Ltd from Scotland, UK (MAXOMEGA). The relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 5 below. The resulting novel composition comprises 55.74% EPA, 39.26% DPA, 2.39% HPA, 97.44% omega-3- pentaenoic acids, and 98.06% total omega-3 fatty acids (all Area%).
  • a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 96:4 the intermediates KD-PUR 900EE KD-Pharma and MAXOMEGA DPA95 FFA converted to ethyl ester, respectively. These intermediates were prepared and commercially offered for sale by KD-Pharma Germany (KD-Pharma) and Equateq Ltd from Scotland, UK (MAXOMEGA). The relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 6 below. The resulting novel composition comprises 89.27% EPA, 4.45% DPA, 3.82% HPA, 97.54% omega-3- pentaenoic acids, and 98.54% total omega-3 fatty acids (all Area%).
  • a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 91 .8:8.2 the intermediates KD-PUR 910EE KD-Pharma and DPA95 FFA converted to ethyl ester, respectively.
  • the relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 7 below.
  • the ethyl ester composition of Example 4 may be converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" below. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
  • Fatty Acid Ethyl Ester (FAEE GMP, approx. 3mmol/g) oil is brought into a closed heated/cooled reaction chamber under nitrogen atmosphere (preferably with pressure control), and heated to 50-60 degree Celcius under stirring.
  • Step 4 Repeat Step 4 several times ( ⁇ 2x) to remove ethanol and NaCI.
  • Example 3 The ethyl ester composition of Example 3 is converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" above. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
  • Example 6 The ethyl ester composition of Example 6 is converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" above. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
  • Example 4 The composition of Example 4 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
  • the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Accucaps in Canada for fish oils or by any other documented and operational encapsulation method.
  • the fill mass of the oil is approximately 1.08 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids ethyl esters per capsule.
  • the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
  • Example 9 The composition of Example 9 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
  • the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Banner in High Point, NC, for fish oils or by any other documented and operational encapsulation method.
  • the fill mass of the oil is approximately 1 .09 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids per capsule.
  • the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
  • Example 5 The composition of Example 5 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100mL of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization.
  • the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Catalent in St.Petersburg, FL, for fish oils or by any other documented and operational encapsulation method.
  • the fill mass of the oil is approximately 1 .05 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids ethyl esters per capsule.
  • the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
  • Example 14 The composition of Example 10 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
  • the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
  • the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Banner in High Point, NC, for fish oils or by any other documented and operational encapsulation method.
  • the fill mass of the oil is 1 .06 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids per capsule.
  • the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
  • a patient is diagnosed with vascular disease. Thereupon, the patient may be initiated on daily treatment with one of the encapsulated compositions according to Examples 10, 1 1 , 12 or 13. Four capsules per day are administered to this patient (4g/d).
  • a patient is treated as per Example 15. The treatment results in significant reduction of the occurrence of MACE.
  • DPA Docosapentaenoic acid 60 100 80
  • DHA Docosahexaenoic acid
  • DPA Docosapentaenoic acid
  • EPA:DPA ratio is between 8 and 15, the HPA: DPA ration between 0.05 and 1 , the DPA:DHA ratio more than 2.4, preferably more than 4, more preferably more than 6, most preferably more than 10, and the EPA:DHA ratio more than 32, preferably more than 38, more preferably more than 80, most preferably more than 95.
  • the EPA, HPA, DPA and DHA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
  • the EPA:HPA ratio is between 0.25 and 12
  • the DPA:EPA ratio is between 13 and 63
  • the DPA:HPA ration between 13 and 190
  • the EPA:DHA ratio more than 00.6, preferably more than 1.5, more preferably more than 2.4, most preferably more than 6.
  • the EPA, HPA, DPA and DHA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
  • the DPA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
  • a mixture of DPA and EPA was prepared by combining 1 g DPA Ethyl Ester (SE-133-III) with 10g EPA Ethyl Ester, 914 mg/g (KD Pharma FM13001 ) in 150ml of 95% ethanol/water containing 35ml of 2M sodium hydroxide. This reaction mixture was stirred overnight at ambient temperature. Tic analysis showed complete conversion of the ethyl esters to the corresponding acids. The reaction mixture was cooled in an ice bath, acidified with 6N hydrochloric acid and concentrated on a rotavap under reduced pressure. Water and ethyl acetate were added, the phases separated and the aqueous residue extracted with ethyl acetate.
  • a fatty acid composition comprising at least 50% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 60% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1.
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 70% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 75% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 80% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 85% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1.
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 90% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • a fatty acid composition comprising at least 95% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 2% docosapentaenoic acid (DPA; C22:5-n3).
  • DPA docosapentaenoic acid
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 5% docosapentaenoic acid (DPA; C22:5-n3).
  • DPA docosapentaenoic acid
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 7% docosapentaenoic acid (DPA; C22:5-n3).
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 8% docosapentaenoic acid (DPA; C22:5-n3).
  • DPA docosapentaenoic acid
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 12% docosapentaenoic acid (DPA; C22:5-n3).
  • composition according to one of the preferred embodiments 1 through 8 comprising at least 15% docosapentaenoic acid (DPA; C22:5-n3).
  • DPA docosapentaenoic acid
  • composition according to one of the preferred embodiments 1 through 17, comprising no more than 95% EPA.
  • composition according to one of the preferred embodiments 1 through 22, comprising no more than 3% arachidonic acid (C22:4-n6).
  • composition according to one of the preferred embodiments 1 through 22, comprising no more than 2% arachidonic acid (C22:4-n6).
  • composition according to one of the preferred embodiments 1 through 22, comprising no more than 1 % arachidonic acid (C22:4-n6).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 0.01 % heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 0.3% heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 0.5% heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 1 % heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 2% heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 3% heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 4% heneicosapentaenoic acid (C21 :5-n3).
  • composition according to one of the preferred embodiments 1 through 27, comprising at least 5% heneicosapentaenoic acid (C21 :5-n3).
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 5% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 4% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 3% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 2% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1.5% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1.25% omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1 % omega-3 fatty acids that are not omega-3- pentaenoic acids.
  • composition according to one of the preferred embodiments through 44 wherein the EPA:DPA ratio is between 5:1 and 1 :1.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 65% and 95% EPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 75% and 95% EPA.
  • a composition according to one of the preferred embodiments 1 through 44 comprising between 80% and 95% EPA.
  • a composition according to one of the preferred embodiments 1 through 44 comprising between 85% and 95% EPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 90% and 95% EPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 2% and 10% DPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 20% DPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 30% DPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 50% DPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 75% DPA.
  • composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 90% DPA.
  • a fatty acid composition according to one of the preferred embodiments 94 through 97 also comprising a suitable anti-oxidant in a concentration sufficient to protect the fatty acids of the composition from oxidation.
  • a pharmaceutically suitable formulation comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 100 and 10,000 mg.
  • a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 250 and 1 ,250 mg.
  • a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 500 and 1 ,100 mg.
  • a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 100 and 10,000 mg.
  • a method of treatment according to preferred embodiments 03 through 105 in which the subject is a patient diagnosed with high triglycerides (equal to or more than 200 mg/dL but less than 500 mg/dL).
  • 108. A method of treatment according to preferred embodiments 103 through 105, in which the subject is a patient already undergoing treatment with a statin and then diagnosed with high triglycerides (equal to or more than 200 mg/dL but less than 500 mg/dL).
  • a method of treatment according to preferred embodiments 103 through 105 in which the subject is a patient diagnosed with mixed dyslipidemia with TG 200- 499 mg/dL and LDL-cholesterol equal to or more than 130 mg/dL.
  • a method of treatment according to preferred embodiments 103 through 105 in which the subject is a patient diagnosed with mixed dyslipidemia with TG 300- 700 mg/dL and LDL-cholesterol equal to or more than 130 mg/dL.
  • the composition of claim 1 wherein the ratio of EPA to DPA (EPA:DPA) is between 15:1 to 8:1.
  • An orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-pentaenoic acids, salts, esters, or derivatives thereof, wherein the composition comprises eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), and wherein the ratio of DHA to EPA (DHA:EPA) is less than 1 :20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 .
  • EPA eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • DHA docosahexaenoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pouvant être administrée par voie orale comprenant des acides gras comprenant des acides gras oméga 3, des sels ou des dérivés de ceux-ci. Ces compositions peuvent être utilisées pour le traitement ou la prophylaxie d'une maladie dyslipidémique, cardio-vasculaire, du système nerveux central, inflammatoire et d'autres maladies/pathologies ou facteurs de risque associés. La présente invention concerne des compositions d'acide gras oméga 3 et des méthodes de traitement, de prévention, de réduction de l'occurrence de symptômes associés à une maladie coronarienne (CHD), une maladie vasculaire, une athérosclérose ou des pathologies associées, et d'amélioration desdits symptômes.
EP13878433.5A 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation Withdrawn EP2968246A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP2968246A1 true EP2968246A1 (fr) 2016-01-20
EP2968246A4 EP2968246A4 (fr) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Country Status (4)

Country Link
EP (2) EP2968246A4 (fr)
JP (2) JP2016518315A (fr)
CA (2) CA2905671A1 (fr)
WO (4) WO2014158256A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233074T3 (pl) 2014-12-15 2023-02-06 Dsm Ip Assets B.V. Leczenie niealkoholowych stłuszczeniowych chorób wątroby
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
EP3456328A4 (fr) * 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, et application et préparation pharmaceutique de cette dernière
KR20190113520A (ko) * 2017-02-09 2019-10-08 에스.엘.에이. 파르마 에이지 유리지방산으로서 고도로 정제된 에이코사펜타엔산의 궤양성 대장염 환자의 분변 칼프로텍틴 레벨의 감소 및 임상 재발 방지
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
PE20250163A1 (es) * 2019-10-25 2025-01-22 Nuseed Nutritional Us Inc Composiciones enriquecidas de acidos grasos poliinsaturados
CN118993893B (zh) * 2024-08-07 2025-06-17 蓝平 一种epa衍生物及其制备方法与用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104856A1 (en) * 2003-05-05 2007-05-10 Hakon Standal Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (fr) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
BRPI0516803A (pt) * 2004-11-19 2008-09-23 Martek Biosciences Corp oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2007058523A1 (fr) * 2005-11-17 2007-05-24 N.V. Nutricia Composition comprenant de l'acide docosapentaenoique
KR100684642B1 (ko) * 2006-09-14 2007-02-22 주식회사 일신웰스 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법
KR101383006B1 (ko) * 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
ES2894340T3 (es) * 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
WO2011050474A1 (fr) * 2009-10-29 2011-05-05 Acasti Pharma, Inc. Compositions de phospholipides thérapeutiques concentrées
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8846604B2 (en) * 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content
EP2861227A4 (fr) * 2012-06-17 2016-01-27 Matinas Biopharma Inc Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2014143275A1 (fr) 2014-09-18
JP2016518315A (ja) 2016-06-23
WO2014165190A2 (fr) 2014-10-09
CA2905671A1 (fr) 2014-09-18
JP2016512544A (ja) 2016-04-28
CA2905795A1 (fr) 2014-10-09
EP2986148A2 (fr) 2016-02-24
WO2014158256A1 (fr) 2014-10-02
EP2968246A4 (fr) 2016-08-03
WO2014165190A3 (fr) 2015-01-29
WO2014143272A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
US20210205254A1 (en) Omega-3 pentaenoic acid compositions and methods of use
EP2968246A1 (fr) Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
WO2014179325A1 (fr) Formulations d'acides gras oméga-3 destinées à être utilisées comme traitement pharmaceutique
AU2019216634A1 (en) Omega-3 pentaenoic acid compositions and methods of use
WO2014179341A1 (fr) Traitement par des compositions d'acide gras oméga-3
US20140194512A1 (en) Compositions comprising docosapentaenoic acid and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201